The article presents a case study of a 17-year-old boy who was admitted to the hospital due to diabetic ketoacidosis (DKA) after administration of a mammalian target-of-rapamycin (mTOR) inhibitors. The patient is reported to have no typical diabetes-related clinical backgrounds. The case alerts medical staff to a risk of mTOR inhibitor-triggered severe hyperglycemia after transplantation.